<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) is a condition that involves deterioration in cognitive and non-cognitive areas </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> is the defining symptom evaluated during clinical trials, changes in non-cognitive areas such as behavior, global functioning and activities of daily living are assessed because they assist in determining quality of life and overall well-being </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy has focused traditionally on preventing and controlling risk factors, as no approved treatments are currently available for these patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="38462">Acetylcholinesterase inhibitors</z:chebi> (AChEIs), the treatment of choice in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), are a potential treatment option for patients with VaD </plain></SENT>
<SENT sid="4" pm="."><plain>Galantamine, an AChEI with nicotinic receptor modulation, has demonstrated clinically relevant benefits (cognition, global functioning, functional ability, behavior) in patients with either AD with cerebrovascular disease (AD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) or probable VaD in a 6-month, randomized, double-blind, placebo-controlled study </plain></SENT>
</text></document>